OverviewSuggest Edit

Keros Therapeutics is a biotechnology company dedicated to the discovery and development of therapeutics for hematological and musculoskeletal disorders. Its lead protein therapeutic product candidate, KER-050, is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. Keros Therapeutics' small molecule product candidate, KER-047, is designed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva. The company also develops KER-01, a preclinical protein therapeutic product candidate that is designed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

TypePublic
Founded2015
HQLexington, MA, US
Websitekerostx.com

Latest Updates

Employees (est.) (Dec 2019)23
Job Openings11
Revenue (FY, 2020)$0(-100%)
Share Price (Sept 2021)$30.7(-1%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Keros Therapeutics

Jasbir Seehra

Jasbir Seehra

CEO & Director
Jennifer Lachey

Jennifer Lachey

Chief Scientific Officer
Claudia Ordonez

Claudia Ordonez

Chief Medical Officer
Keith Regnante

Keith Regnante

Chief Financial Officer
Ran Nussbaum

Ran Nussbaum

Chairman
Nima Farzan

Nima Farzan

Director
Show more

Keros Therapeutics Office Locations

Keros Therapeutics has an office in Lexington
Lexington, MA, US (HQ)
99 Hayden Ave suite 120 building e
Show all (1)

Keros Therapeutics Financials and Metrics

Keros Therapeutics Revenue

USD

Net income (FY, 2020)

(45.4m)

EBIT (FY, 2020)

(46.7m)

Market capitalization (17-Sept-2021)

715.9m

Closing stock price (17-Sept-2021)

30.7

Cash (31-Dec-2020)

265.9m

EV

451.8m
Keros Therapeutics's current market capitalization is $715.9 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

10.0m10.0m

Revenue growth, %

General and administrative expense

1.6m3.2m

R&D expense

10.1m17.4m
Quarterly
USDQ1, 2020Q2, 2020

EBIT

(10.5m)(10.9m)

Pre tax profit

(12.1m)(10.8m)

Income tax expense

(172.0k)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

23.3m7.0m265.9m

Prepaid Expenses

2.3m381.0k1.9m

Current Assets

25.5m8.9m267.7m

PP&E

645.0k708.0k724.0k
Quarterly
USDQ1, 2020Q2, 2020

Cash

54.5m144.7m

Prepaid Expenses

1.2m3.8m

Current Assets

58.5m148.5m

PP&E

822.0k781.0k
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(1.3m)(12.3m)(45.4m)

Depreciation and Amortization

153.0k208.0k278.0k

Accounts Payable

(2.0k)1.3m61.0k

Cash From Operating Activities

7.0m(16.0m)(36.9m)
Quarterly
USDQ1, 2020Q2, 2020

Net Income

(11.9m)(22.6m)

Depreciation and Amortization

63.0k131.0k

Accounts Payable

(193.0k)2.8m

Cash From Operating Activities

(8.1m)(18.0m)
USDFY, 2018

Debt/Equity

-0.1 x

Financial Leverage

-3.8 x
Show all financial metrics

Keros Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Keros Therapeutics Australia

Keros Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Keros Therapeutics Online and Social Media Presence

Embed Graph

Keros Therapeutics News and Updates

Keros Therapeutics to Participate in Two Upcoming Healthcare Conferences

LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders…

Keros Therapeutics Appoints Simon Cooper, M.B.B.S. as Chief Medical Officer

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders …

Keros Therapeutics Announces Preliminary Results from its Phase 2 Clinical Trial Evaluating KER-050 in Patients with Myelodysplastic Syndromes

LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders …

Keros Therapeutics Presents Preclinical Data from ALK2 and KER-050 Hematology Programs at the European Hematology Association EHA2021 Virtual Congress

LEXINGTON, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders …

Keros Therapeutics to Present at the Jefferies Virtual Healthcare Conference

LEXINGTON, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders w…

Keros Therapeutics Announces Issuance of U.S. Patent for Use of Therapeutic Proteins in Treatment of Musculoskeletal Disorders

LEXINGTON, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders w…
Show more

Keros Therapeutics Blogs

Keros Therapeutics Closes $56 Million Series C Financing to Advance its Programs in Hematologic and Musculoskeletal Disorders

Lexington, Massachusetts – March 4, 2020 – Keros Therapeutics, Inc., a biotechnology company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need, today announced the close o…

Keros Therapeutics Appoints Keith Regnante as Chief Financial Officer

LEXINGTON, Mass.  – Keros Therapeutics, Inc., a privately-held biotechnology company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need, today announced the appointment of …

Keros Therapeutics Frequently Asked Questions

  • When was Keros Therapeutics founded?

    Keros Therapeutics was founded in 2015.

  • Who are Keros Therapeutics key executives?

    Keros Therapeutics's key executives are Jasbir Seehra, Jennifer Lachey and Claudia Ordonez.

  • How many employees does Keros Therapeutics have?

    Keros Therapeutics has 23 employees.

  • Who are Keros Therapeutics competitors?

    Competitors of Keros Therapeutics include Capricor Therapeutics, Audentes Therapeutics and Regulus Therapeutics.

  • Where is Keros Therapeutics headquarters?

    Keros Therapeutics headquarters is located at 99 Hayden Ave suite 120 building e, Lexington.

  • Where are Keros Therapeutics offices?

    Keros Therapeutics has an office in Lexington.

  • How many offices does Keros Therapeutics have?

    Keros Therapeutics has 1 office.